The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
Fig 4
Duvelisib in combination with dexamethasone, ibrutinib or everolimus results in greater tumor growth inhibition compared to monotherapies.
DOHH2 xenografts treated with duvelisib (50 mg/kg, PO, BID), dexamethasone (5 mg/kg, IP, Q3D) or the combination (A) or duvelisib (12.5 mg/kg, PO, BID), ibrutinib (12.5 mg/kg, PO, BID) or the combination (B). The combination groups showed significant growth inhibition compared to the monotherapies (A: p ≤ 0.006; B: p ≤ 0.001) C. SuDHL-4 xenografts treated with duvelisib (12.5 mg/kg PO, BID), everolimus (2.5 mg/kg, PO, QD) or the combination. Tumor growth was significantly inhibited in the combination group compared to monotherapies (p < 0.008).